SANGAMO THERAPEUTICS, INC false 0001001233 0001001233 2021-01-14 2021-01-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2021

SANGAMO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 000-30171 |  | 68-0359556
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (IRS Employer ID Number)

7000 Marina Blvd., Brisbane, California |  | 94005
(Address of principal executive offices) |  | (Zip Code)

(510) 970-6000

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.01 par value per share |  | SGMO |  | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 | Other Events.

Sangamo Therapeutics, Inc. is filing this report for the purpose of filing a copy of the slides containing updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for patients with severe hemophilia A, that were presented on December 7, 2020 at the 62nd American Society of Hematology (ASH) Annual Meeting (the “Data Presentation”). A copy of the Data Presentation is attached as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01 | Financial Statements and Exhibits.

(d) | Exhibits.

Exhibit No. |  | Description
99.1 |  | 2020 American Society of Hematology (ASH) Annual Meeting Data Presentation
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  |  | SANGAMO THERAPEUTICS, INC.
Dated: January 14, 2021 |  |  |  | By: |  | /s/ GARY H. LOEB
|  |  |  | Name: |  | Gary H. Loeb
|  |  |  | Title: |  | Executive Vice President & General Counsel